Implantation or Injectable Dosage Form New Animal Drugs: Ceftiofur Crystalline Free Acid
Federal Register: October 8, 2008 (Volume 73, Number 196)
Rules and Regulations
Page 58871-58872
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
DOCID:fr08oc08-3
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration 21 CFR Part 522
Docket No. FDA-2008-N-0039
Implantation or Injectable Dosage Form New Animal Drugs;
Ceftiofur Crystalline Free Acid
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Pharmacia & Upjohn Co., a Division of
Pfizer, Inc. The supplemental NADA provides for veterinarian prescription use of ceftiofur crystalline free acid injectable suspension for the treatment
Page 58872
of bovine foot rot (interdigital necrobacillosis).
DATES: This rule is effective October 8, 2008.
FOR FURTHER INFORMATION CONTACT: Donald A. Prater, Center for
Veterinary Medicine (HFV-130), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855, 240-276-8343, e-mail: donald.prater@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Pharmacia & Upjohn Co., a Division of
Pfizer, Inc., 235 East 42d St., New York, NY 10017, filed a supplement to NADA 141-209 for EXCEDE (ceftiofur crystalline free acid) Sterile
Suspension. The supplemental NADA provides for veterinarian prescription use of ceftiofur crystalline free acid injectable suspension for the treatment of bovine foot rot (interdigital necrobacillosis) in beef, non-lactating dairy, and lactating dairy cattle. The application is approved as of August 15, 2008, and the regulations are amended in 21 CFR 522.313a to reflect the approval.
In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), summaries of the safety and effectiveness data and information submitted to support approval of these applications may be seen in the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), this supplemental approval qualifies for 3 years of marketing exclusivity beginning on the date of approval. The 3 years of marketing exclusivity apply only to the bovine foot rot indication for which this supplement is approved.
The agency has determined under 21 CFR 25.33(d)(5) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
This rule does not meet the definition of ``rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
List of Subjects in 21 CFR Part 522
Animal drugs. 0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is amended as follows:
PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS 0 1. The authority citation for 21 CFR part 522 continues to read as follows:
Authority: 21 U.S.C. 360b. 0 2. In Sec. 522.313a, amend paragraph (e)(2)(ii) by adding a third sentence to read as follows:
Sec. 522.313a Ceftiofur crystalline free acid.
* * * * *
(e) * * *
(2) * * *
(ii) * * * For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and
Porphyromonas levii in beef, non-lactating dairy, and lactating dairy cattle.
* * * * *
Dated: September 29, 2008.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
FR Doc. E8-23830 Filed 10-7-08; 8:45 am
BILLING CODE 4160-01-S